Shares Jump After H1N1 Patent License Win
- Shares of VeriChip Corp tripled after the company said it had been granted
an exclusive license to two patents, which will help it to develop implantable
virus detection systems in humans. The
patents, held by VeriChip partner Receptors LLC, relate to biosensors that
can detect the H1N1 and other viruses, and biological threats such as methicillin-resistant
Staphylococcus aureus, VeriChip said in a statement.
will combine with VeriChip's implantable radio frequency identification
devices to develop virus triage detection systems. The triage system will
provide multiple levels of identification -- the first will identify the
agent as virus or non-virus, the second level will classify the virus and
alert the user to the presence of pandemic threat viruses and the third
level will identify the precise pathogen, VeriChip said in a white paper
published May 7, 2009.
of VeriChip were up 186 percent at $3.28 Monday late afternoon trade on
Nasdaq. They had touched a year high of $3.43 earlier in the session.